Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

VEGF and HIF Pathway Inhibition Point Toward an Increasingly Tolerable RCC Armamentarium

August 25th 2023

Qian (Janie) Qin, MD, discusses the current RCC treatment landscape, ongoing research with belzutifan combination therapies, and considerations for investigating CAR T-cell therapy in patients with solid tumors.

Case Studies Illustrate the Importance of Nuanced Treatment Discussions in Advanced RCC

August 25th 2023

Hans Hammers, MD, PhD, outlines 3 cases of patients with renal cell carcinoma, detailing how each patient’s disease presented and how clinicians proceeded with treatment.

Dr Hammers on Ongoing Investigations in Advanced RCC

August 23rd 2023

Hans Hammers, MD, PhD, discusses ongoing and planned investigations with the use of HIF2α inhibitors and triplet therapies in patients with advanced renal cell carcinoma.

Dr McDermott on the Eligibility Criteria of the LITESPARK-024 Trial in RCC

August 21st 2023

David F. McDermott, MD, discusses the ongoing, randomized, phase 1/2 LITESPARK-024 trial in patients with advanced renal cell carcinoma, highlighting the eligibility criteria for this clinical trial.

Belzutifan Improves PFS in Pretreated Advanced RCC

August 18th 2023

Treatment with belzutifan demonstrated a statistically significant and clinically meaningful improvement in progression-free survivalcompared with everolimus in patients with advanced renal cell carcinoma that has progressed on prior PD-1/PD-L1 and VEGF inhibitors, in sequence or in combination.

Dr Yentz on Treatment Decisions for Patients With Kidney Cancer

August 17th 2023

Sarah Elizabeth Yentz, MD, discusses how she decides between an immunotherapy agent plus a TKI combination vs 2-agent immunotherapy for patients with renal cell carcinoma.

Molecular Subtyping and Surgical Sequencing Broaden Immunotherapy Applications in RCC

August 14th 2023

Tian Zhang, MD, discusses unanswered questions regarding molecular drivers of kidney cancer that the OPTIC RCC trial aims to answer, next steps with this research, and the potential benefits of receiving systemic therapy prior to undergoing cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.

Evaluation of Novel Agents and Combinations Aims to Improve Outcomes in Frontline RCC

August 10th 2023

Ulka Nitin Vaishampayan, MBBS, discusses factors to consider for choosing between immuno-oncology/immuno-oncology and VEGF TKI/immuno-oncology combinations for the frontline treatment of patients with renal cell carcinoma, areas of ongoing research in this disease, and treatment updates across the prostate cancer spectrum.

SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalumab in MET-Driven Papillary RCC

August 10th 2023

The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.

Dr Kraft on VEGF Inhibitor–Induced Hypertension in RCC

August 10th 2023

Shawna Kraft, PharmD, BCOP, discusses the incidence and mitigation of VEGF inhibitor–induced hypertension in patients with renal cell carcinoma (RCC).

Stereotactic Radiation Strategies May Bolster RCC Multi-Modality Management Efforts

August 3rd 2023

Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation in patients with localized RCC who are unfit for surgery, research findings indicating improved outcomes in patients who received radiation for metastatic disease, and how this radiation technique may work in concert with systemic therapy.

Investigators Pursue the Role of the Microbiome on Immunotherapy Treatment in RCC

August 1st 2023

Pedro C. Barata, MD, MSc, discusses the importance of further exploring the facets of manipulating the microbiome to augment responses with immunotherapy in RCC, as well as the promise of the bifidogenic live bacterial product, CBM588.

Dr Sun on Ongoing Research Efforts Examining Clonal Hematopoiesis in RCC

July 31st 2023

Maxine Sun, PhD, MPH, discusses ongoing research efforts dedicated to examining the relationship between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma.

FDA Grants Fast Track Designation to IVS-3001 for Renal Cell Carcinoma

July 31st 2023

The FDA has granted fast track designation IVS-3001 for use as a potential therapeutic option in patients with renal cell carcinoma.

Dr Vaishampayan on Toxicities Associated With Various Treatments in RCC

July 27th 2023

Ulka Nitin Vaishampayan, MBBS, discusses toxicities associated with various treatment options for patients with renal cell carcinoma.

Dr Barata on the Relationship Between the Microbiome and Immunotherapy in RCC

July 26th 2023

Pedro Barata, MD, MSc, discusses the relationship between the gut microbiome and treatment with immunotherapy in patients with renal cell carcinoma.

Renal Cell Carcinoma: Future Evolutions in Care

July 24th 2023

Shared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.

Selecting Optimal Therapy for Advanced Non-Clear Cell RCC

July 24th 2023

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Rini Expands on Key Clinical Trial Updates in GU Cancers from the 2023 ASCO Annual Meeting

July 20th 2023

Brian I. Rini, MD, FASCO, highlights key clinical trial updates from the genitourinary cancers landscape presented at the 2023 ASCO Annual Meeting, details the implications of the CONTACT-03 data, expands on the long-term data from the phase 3 KEYNOTE-426 trial in clear cell RCC, discusses findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer, and more.

Dr Signoretti on the Development of Novel Biomarkers in RCC Using Tissue-Based Analyses

July 19th 2023

Sabina Signoretti, MD, discusses research into the development of novel spatial biomarkers in renal cell carcinoma utilizing tissue-based in situ analyses.